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Abstract
Bronchopulmonary dysplasia (BPD) is a chronic lung disease of prematurity. Over the years, the 
BPD phenotype has evolved, but despite various advances in neonatal management approaches, 
the reduction in the BPD burden is minimal. With the advent of surfactant, glucocorticoids, and 
new ventilation strategies, BPD has evolved from a disease of structural injury into a new BPD, 
marked by an arrest in alveolar growth in the lungs of extremely premature infants. This deficient 
alveolar growth has been associated with a diminution of pulmonary vasculature. Several 
investigators have described the epithelial/vascular co-dependency and the significant role of 
crosstalk between vessel formation, alveologenesis, and lung dysplasia’s; hence identification and 
study of factors that regulate pulmonary vascular emergence and inflammation has become crucial 
in devising effective therapeutic approaches for this debilitating condition. The potent 
antiangiogenic and proinflammatory protein Endothelial Monocyte Activating Polypeptide II 
(EMAP II) has been described as a mediator of pulmonary vascular and alveolar formation and its 
expression is inversely related to the periods of vascularization and alveolarization in the 
developing lung. Hence the study of EMAP II could play a vital role in studying and devising 
appropriate therapeutics for diseases of aberrant lung development, such as BPD. Herein, we 
review the vascular contribution to lung development and the implications that vascular mediators 
such as EMAP II have in distal lung formation during the vulnerable stage of alveolar genesis.
Keywords
AIMP1; SCYE1; bronchopulmonary dysplasia; prematurity
© 2014 Wiley Periodicals, Inc.
*Correspondence to: Margaret A. Schwarz, MD, Indiana University School of Medicine South Bend, 1234 Notre Dame Avenue, South 
Bend, IN 46617. schwarma@iupui.edu. 
NIH Public Access
Author Manuscript
Birth Defects Res A Clin Mol Teratol. Author manuscript; available in PMC 2015 March 12.
Published in final edited form as:
Birth Defects Res A Clin Mol Teratol. 2014 March ; 100(3): 180–188. doi:10.1002/bdra.23234.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Introduction
LUNG MORPHOGENESIS AND PULMONARY ENDOTHELIUM: THE CROSS-TALK
The human vascular network is composed of two major circulations, systemic and 
pulmonary, connected in series and separated by the heart. Blood vessel formation is a 
process that is highly regulated, involving not only proliferation and differentiation of the 
vasculature, but also regression and stasis of these structures (Scavo et al., 1998). Hence, 
these processes warrant a delicate balance between the proangiogenic and antiangiogenic 
factors. Two identified and distinct processes; vasculogenesis and angiogenesis are 
responsible for the majority of vascularization during fetal growth and development (Poole 
and Coffin, 1989; Coffin et al., 1991). First, vasculogenesis is the formation and 
organization of angioblasts into linear aggregates that form primitive capillary plexus during 
embryogenesis before the formation of vascular structures. Second, angiogenesis is the 
extension of previously formed vessels into undervascularized regions where differentiated 
endothelial cells proliferate, sprout from previously formed vessels, and form new vascular 
structures (Jeffery and Reid, 1973; Burri et al., 1974; Kauffman, 1981). Defects in 
endothelial cell development and vessel formation and function lead to embryonic lethality 
and are important in the pathogenesis of vascular diseases (Park et al., 2013).
The pulmonary circulation is a highly specialized vascular bed that physically and 
functionally connects the heart and the lungs (Peng and Morrisey, 2013). Its formation 
involves a complex, multistep process that includes formation of primitive vascular 
networks; remodeling with local regression and branching and then specialization toward 
larger vessels like arteries, veins, and lymphatics (deMello et al., 1997; Galambos and 
deMello, 2007). A multitude of growth factors play a role in these processes, interaction of 
which leads to various budding and branching events that generate a tree like system of 
capillaries and epithelium, which forms the mature lung organ capable of air exchange at the 
alveolar endothelial cell interface (Copland and Post, 2004; Cardoso and Lu, 2006; Maeda et 
al., 2007; Millien et al., 2008; Schwarz and Cleaver, 2009). The chronological stages of lung 
development based on growth of specific pulmonary vasculature and epithelial structures are 
consistent across all mammalian species (Ten Have-Opbroek, 1981; Kimura and Deutsch, 
2007). There are five phases of structural lung development that occur at progressive times 
during gestation, namely embryonic, pseudoglandular, canalicular, saccular, and alveolar 
stages (Loosli and Potter, 1959). The timing of the phases is approximate, with overlap 
between the various stages and variation among different fetuses (Zeltner and Burri, 1987). 
The highly proliferative and vascular canalicular stage occurs between the 16th and 27th 
weeks of gestation. The terminal sac formation, or the saccular stage encompasses the period 
from 28 to 36 weeks, after which the alveolar stage starts. The canalicular and saccular 
stages are the most vulnerable periods in lung development; any aberration during these 
stages could possible result in an arrest of alveolar development leading to lung dysplasias 
such as bronchopulmonary dysplasia (BPD) (Baraldi and Filippone, 2007). Using different 
ablative strategies to eliminate the lung vasculature, both in vivo and in lung explants, it has 
been shown that the proximity of the vasculature is essential for distal alveolar formation 
and patterning airway branching (Schwarz et al., 2004).
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Increasing evidence suggests that blood vessels actively promote alveolar growth during 
lung development and contribute to the maintenance of alveolar structures (Thebaud and 
Abman, 2007; Schwarz et al., 2009; Ding et al., 2011). Within the complex emerging 
vascular network, proangiogenic vascular endothelial growth factor (VEGF) and its 
receptors, VEGFR1 and VEGFR2, are essential for vascular development and embryonic 
survival (Carmeliet et al., 1996a, 1996b), as modulators of endothelial differentiation, blood 
vessel formation, and morphogenesis (Ferrara et al., 2003). At a mechanistic level, epithelial 
expressed VEGF prompts endothelial cells to move toward the epithelium where arrival of 
the endothelium to the epithelial interface coincides with epithelial differentiation during the 
proliferative, canalicular stage (Schwarz et al., 2009). In addition to being a master regulator 
of blood vessel formation, VEGFR2 has been demonstrated to directly promote the 
expansion of the lymphatic network and further define the molecular mechanisms 
controlling development of the lymphatic vascular system (Dellinger et al., 2013). Factors 
controlling the transcriptional regulation of VEGF and VEGFR mediate distal alveolar 
development. For example, using chromatin precipitation, NF-κB was found to be a direct 
regulator of VEGFR2 transcription. Blockade of NF-κB induced a reduction in neonatal 
pulmonary vasculature and was associated with alveolar simplification (Iosef et al., 2012). 
Hypoxia-inducible factors (HIFs), oxygen responsive transcription factors that influence 
VEGF and VEGF receptor expression influence alveolar formation. A recent study suggests 
that prenatal hypoxia insults, at least in late gestation, influence pulmonary VEGF and 
VEGF receptor expression through the down-regulation of HIF pathways and impair fetal 
lung growth and maturation (Tsao and Wei, 2013). Identification of those factors such as 
HIF that promote normal alveolar development may be useful targets for alveolar 
regeneration (Vadivel et al., 2013).
Not all growth factors that influence endothelial cells specifically target only the 
endothelium. In contrast to vascular growth factors, proteins previously identified as 
vascular markers have recently been shown to extend their influence beyond endothelial cell 
boundaries. For example, Ephrin-B2, a tyrosine kinase ligand is involved in angiogenesis 
and is defined as a marker of endothelial arterial fate specification. EphrinB2 is necessary 
for normal alveolar development and exerts therapeutic benefit in protecting the lung from 
O2-induced alveolar injury and pulmonary hypertension (Vadivel et al., 2012). Bennett et al. 
determined that the ephrin-B2 ligand found on primitive arterial vessels, also governed 
alveolar growth and mechanics beyond the confines of the endothelium as ephrin-B2 reverse 
signaling also mediated distal alveolar formation, alveolar fibrillogenesis (the deposition of 
fibronectin in the distal alveoli), and pulmonary compliance (Bennett et al., 2013). Further 
supporting a more extensive role of endothelial selective factors in pulmonary 
morphogenesis was demonstrated by the mutation of the vascular tone mediator of smooth 
muscle contraction endothelial nitric oxide synthetase, where transgenic mice resulted in 
capillary hypoperfusion, misaligned pulmonary veins, and a paucity of distal alveolar 
branches were identified (Han et al., 2004).
Of interest, the lung phenotype of endothelial nitric oxide synthase mutants closely 
resembles alveolar capillary dysplasia in humans, where a universally fatal form of 
persistent pulmonary hypertension of the newborn, presents with defective lung vascular 
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development and respiratory distress in newborn (Han and Stewart, 2006). However, an 
alternative consideration is that disturbances in the vascular mediators ephrin-B2 and 
endothelial nitric oxide synthase disrupted the vasculature that itself was necessary for other 
aspects of alveolar development. Therefore, vascular growth factors have been described to 
work in a very complex and coordinated manner through various pathways to form the 
pulmonary vasculature, which is critical in alveologenesis and gas exchange. A reduction in 
vascular growth factors, their receptors, or their enhanced degradation can lead to aberrant 
lung development and disease states. One such debilitating disease is BPD in which an arrest 
in pulmonary capillary formation possibly precedes severe alveolar dysplasia in premature 
infants.
ROLE OF ANTIANGIOGENIC PROTEIN: EMAP II IN PULMONARY MORPHOGENESIS
In contrast to the positive roles of angiogenic factors and their receptors, the inhibitory 
vascular factors provide a counterbalance to vessel formation during lung development. One 
such potent antiangiogenic factor, Endothelial Monocyte Activating Polypeptide II (EMAP 
II), plays a significant role in pulmonary vascular development and has been shown to 
inhibit lung neovascularization and airway epithelial morphogenesis (Schwarz et al., 2000a). 
First described as a pro inflammatory mediator (Kao et al., 1992, 1994), EMAP II was later 
determined to have significant antiangiogenic properties. EMAP II is a cytokine-like 
molecule first identified from murine methylcholanthrene A-induced fibrosarcomas (Kao et 
al., 1992) and is synthesized as a 34 kDa pro-form (pro-EMAP II), which is cleaved to the 
22 kDa mature form. The mature form is responsible for most of its described biological 
activities (Kao et al., 1994). Schwarz et al. found that, pro-EMAP II resides on the cell 
membrane where within a proteinase sensitive 44 amino acid residue region, the enzyme 
cathepsin L cleaves pro-EMAP II to within 4 amino acids of the determined N-terminal 
sequence (Zhang and Schwarz, 2002; Liu and Schwarz, 2006). Mechanistically, examination 
of tumors treated with EMAP II suggested that EMAP II targeted endothelial cell viability 
as Schwarz et al. demonstrated that EMAP II induced endothelial cell apoptosis, inhibited 
tumor vessel formation, and suppressed primary and metastatic tumor growth (Schwarz et 
al., 1999a; Berger et al., 2000). Its antiangiogenic potential was further established when 
EMAP II was found to retard local tumor growth, significantly reduce microvessel counts, 
and induce a higher vascular thrombosis rate. Importantly, it was in these studies that EMAP 
II was recognized for its impact on nonendothelial cells, as there was also an associated 
reduction tumor cell proliferation (Schwarz and Schwarz, 2004). In addition to tumor 
vascular regulation, administration of EMAP II markedly diminished levels of herpes 
simplex virus-induced angiogenesis thereby reducing the severity of ocular stromal keratitis 
lesions (Zheng et al., 2001). These studies suggest that EMAP II is an angiostatic mediator 
that suppresses neovascularization.
In lung morphogenesis, where cell proliferation, neo-vascularization, and epithelial cell 
differentiation are the main emphasis, EMAP II plays an important role as a modulator of 
vascular and alveolar morphogenesis. Initial studies of murine pulmonary morphogenesis 
identified EMAP II’s protein and mRNA to have an inverse correlation between expression 
and lung vascularization (Schwarz et al., 1999b). For example, during the embryonic and 
early pseudoglandular stages of lung development, EMAP II expression is high while the 
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vasculature is immature. In contrast, as the distal alveolar structure enters the proliferative 
canalicular stage, EMAP II expression abruptly falls and remains low through postnatal lung 
development with a transient surge of EMAP II protein expression during postnatal days 8 
to 16 corresponding with the microvascular maturation of the lung. Importantly, early 
EMAP II protein and mRNA expression localizes to the epithelial interface with the foregut 
splanchnopleuric mesoderm at a time when expression of the classic early vascular markers 
are not found in that region. During the later vascular stages, EMAP II localizes to the 
perivascular regions of larger vessels suggesting a static role in vessel homeostasis (Schwarz 
et al., 1999b). These findings suggested a significant role for EMAP II in vascular formation 
during pulmonary morphogenesis.
Development of the pulmonary vascular and epithelial interface requires communication and 
interaction between the cellular components to form a function air-exchanging unit. 
Increasing evidence suggests that the vasculature has a critical role in modulating epithelial 
growth. The epithelial lining located deep in the distal airways, is vital to gas exchange. 
Alveolar formation in these distal parts of the lung involves transdifferentiation of alveolar 
type II and alveolar type I cells in direct conjunction with the endothelial cells. EMAP II’s 
temporo-spatial location in this region suggested a role in distal alveolar formation. 
Although targeted ablation of EMAP II in the pulmonary vasculature would specifically 
address this issue, a targeted knockout mouse was not available. Therefore, an allograft 
model of distal lung development and neovascularization that avoided the placental barrier 
was used to determine the impact of EMAP II in lung development (Schwarz et al., 2000b). 
Delivery of exogenous EMAP II during the late pseudoglandular through saccular stages of 
lung development not only inhibited neovascularization, but markedly altered lung 
morphogenesis including a lack of alveolar type I and II cells and the induction of apoptosis. 
In contrast, delivery of an EMAP II function antibody marked increased vessel density and 
the expression of the alveolar type II cell marker surfactant protein (Schwarz et al., 2000a). 
These studies suggested that the vascular mediator EMAP II had a role that extends beyond 
the endothelial cell. In vitro studies defined the interdependence of the epithelial–
mesenchymal interactions and vasculature. Administration of the known vascular inhibitor 
EMAP II to a proxy of alveolar architectural formation, epithelial cyst formation, disrupted 
the organization of epithelial and mesenchymal cells into epithelial cystic structures, 
inhibited vascular development, and induced epithelial apoptosis. Conversely, epithelial cyst 
formation was facilitated by an EMAP II-blocking antibody (Schwarz et al., 2004). 
Although these studies established a link between the antiangiogenic growth factor EMAP II 
and epithelial cell survival, the impact EMAP II had on distal alveolar structural 
organization epithelial differentiation was unclear. A three-dimensional model of fetal lung 
self-assembly was used to better define the impact that EMAP II had on alveolar 
organization. Schwarz et al. (2011) discovered that dissociated fetal lung in the 
pseudoglandular stage had the innate ability to self-assemble into a three-dimensional lung 
formation that mimics structure, polarity, vasculature, and extracellular matrix expression. 
This three-dimensional lung formation, pulmonary body, afforded the ability to identify the 
role that EMAP II had on cell-intrinsic properties that that guide the lungs structural 
organization during morphogenesis by examining epithelial endodermal and mesenchymal 
mesodermal cell interactions (Schwarz et al., 2011). From these studies, it was determined 
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that in lung cellular interactions, EMAP II was able to influence cell–cell interactions by 
increasing the rate of pulmonary body self-assembly while decreasing overall cell–cell 
cohesion. Of interest, EMAP II cohesion effects were exclusively targeted to the 
mesenchymal cell population where it interfered with the mesenchymal cells production of 
the extracellular matrix protein fibronectin. However, the loss of fibronectin deposition and 
altered mesenchymal cell–cell interactions was also associated with an inhibition of 
epithelial cell polarity and surfactant protein C expression. These studies supported the role 
of EMAP II on both mesenchymal and epithelial cell populations in lung structural and 
morphologic development through different molecular mechanisms. Furthermore, these 
findings suggest that lung development may be influenced by the expression and function of 
antiangiogenic proteins through an adhesion-based mechanism with extracellular matrix 
(ECM) -facilitated signaling being a mediator of cell viability and differentiation (Schwarz 
et al., 2011). This concept that EMAP II targeted epithelial cell transdifferentiation through 
an ECM-facilitated signaling was further supported by its ability to disrupt in vitro alveolar 
type II → alveolar type I cell transdifferentiation. Taken together these studies support 
EMAP II’s role as a regulator of distal alveolar structural development that can influence the 
formation of essential and functional gas-exchanging units (Chen et al., 2012).
The observation in in vivo and in vitro models that EMAP II targeted ECM deposition, 
endothelial cell viability, and epithelial cell transdifferentiation suggested that a subset of 
cells engaged in activities that are dependent on cell adhesion and migration were being 
targeted. Mechanistically, excess EMAP II was found to inhibit endothelial cell adhesion to 
fibronectin (FN), disrupt actin stress fibers and disassemble cellular fibronectin matrices. 
Furthermore, EMAP II’s ability to disrupt cellular adhesion to FN was due to its direct 
interaction with integrin alpha5 beta1 in an RGD dependent manner (Schwarz et al., 2005). 
In addition to FN being essential for endothelial cell viability and adhesion, recent studies 
suggest that progression of epithelialization is dependent on FN deposition at epithelial–
mesenchymal interface (Koshida et al., 2005; Larsen et al., 2006; Julich et al., 2009). Taken 
together, EMAP II’s disruption of developing lung fibronectin deposition may interfere with 
distal epithelial transdifferentiation, vessel formation, and sturctural organization.
In contrast to matrix driven mechanisms, alteration in expression levels of VEGFA have 
been shown to markedly influence distal lung dysplasia (Tsao and Wei, 2013). Awasthi et al. 
showed that EMAP II binds to the VEGFR1 and VEGFR2 receptors preventing them from 
interacting with their VEGFA ligand. Furthermore, EMAP II markedly reduces VEGFA 
signaling and phosphorylation of VEGFR1 and VEGFR2 resulting in the inhibition of 
VEGFA mediated endothelial cell proliferation and migration (Awasthi et al., 2009). Of 
interest, HIF-1 alpha, a transcriptional regulator of VEGFA is influenced by EMAP II. 
Recent studies show that EMAP II modulates endothelial cell responses by proteolytic 
degradation of HIF-1 alpha (Tandle et al., 2009) and interfering with VEGF induced 
proangiogenic signaling (Awasthi et al., 2009). EMAP II’s targeted disruption of VEGFA 
transcription and signaling and interference of endothelial cell adhesion may contribute to 
the pathogenesis of lung dysmorphogenesis such as BPD.
In the first ever consideration of the hypothesis that EMAP II expression contributed to 
distal alveolar dysmorphogenesis in premature infants, Quintos-Alagheband et al. had found 
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EMAP II expression to be profoundly elevated in autopsy lung samples of human infants 
with BPD. Tissue obtained from human neonates with pathologic signs of BPD had a 
marked diffuse increase in EMAP II expression in the alveolar region on 
immunohistochemistry (Quintos-Alagheband et al., 2004). In contrast, age-matched control 
infants had minimal expression of EMAP II in this region. Consistent with these findings, 
EMAP II levels were significantly elevated in the perivascular stroma and lung periphery in 
the neonatal baboon model of BPD (Quintos-Alagheband et al., 2004). In this model, 
gestation-matched controls were compared with premature baboons treated in a baboon 
intensive care unit with oxygen as needed. In situ hybridization determined that at baseline 
EMAP II mRNA at 125 days (canalicular stage) is expressed throughout the subepithelium 
of the bronchi and diffusely in the distal alveolar regions whereas its expression in the 
perivascular areas was minimal. By the beginning of the saccular stage, i.e., 140 days, there 
was a slight increase in its perivascular expression, but a decrease in its overall lung 
expression. By term gestation, i.e., 160 and 175 days EMAP II expression was 
predominantly in the perivascular area and minimal in the alveoli. In contrast to its normal 
decline between days 125 and 160; in the preterm baboon model of BPD, EMAP II 
abundance was markedly elevated. EMAP II expression was prematurely accelerated in a 
perivascular distribution and was associated with the dysplastic undervascularized alveolar 
regions of the distal lung consistent with the BPD phenotype. These studies support a strong 
link between BPD and EMAP II expression. The authors speculated that premature birth 
exposes infants to factors which directly or indirectly upregulate EMAP II which then 
negatively influences neovascularization leading to disrupted alveolarization.
EMAP II AND INFLAMMATION
In addition to the role of EMAP II in altering the physiology of angiogenesis, it has been 
described to have transient inflammatory properties (Kao et al., 1992, 1994; Mueller et al., 
2003; Murray et al., 2004, van Horssen et al., 2006a, 2006b; Journeay, Janardhan et al., 
2007; van Horssen et al., 2008). These include the chemotactic effects toward monocytes 
and granulocytes, and direction of leukocyte migration involving an increase in intracellular 
calcium (Kao et al., 1992, 1994). Van Horssen et al. found that EMAP II sensitizes 
endothelial cells to apoptosis by facilitating tumor necrosis factor (TNF) -R1 apoptotic 
signaling by means of TNF-R1-Associated Death Domain (TRADD) mobilization and 
introduce a molecular and antiangiogenic explanation for the TNF sensitizing properties of 
EMAP II in tumors (van Horssen et al., 2006b). It also up regulates production of 
inflammatory molecules like TNF, and interleukin-8 in mononuclear phagocytes and 
polymorph nuclear leukocytes and promotes adhesion of monocytes. (Kao et al., 1992, 
1994; Ko et al., 2001; Park et al., 2002). Murray et al. found that EMAP II causes a dose-
dependent inhibition of proliferation and apoptosis in Jurkat T lymphocytes and mitogen-
activated peripheral blood mononuclear cells and constitutes a component of a novel, 
immunosuppressive pathway in solid tumors (Murray et al., 2004). Later the same authors 
linked EMAP II ability to induce lymphocyte death with hypoxia in colorectal cancer 
(Youssef et al., 2006). Lipopolysacchride causes lung inflammation, and induces rapid 
EMAP II expression in lungs and in models of acute lung injury (Journeay et al., 2007). In 
addition, intratracheal instillation of EMAP II results in monocyte, macrophage and 
granulocyte recruitment without altering the lung expression of interleukin-1β or MIP-2 
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(Journeay et al., 2007). interleukin-1β has been described to be critical in the early phase of 
acute lung inflammation while MIP-2 promotes recruitment of monocytes and granulocytes 
and hence these experiments point toward a direct proinflammatory role of EMAP II on the 
lungs. Proinflammatory environment in the perinatal period, secondary to chorioamnioitis 
(Watterberg et al., 1996), ureaplasma infection (Schelonka et al., 2005), and postnatal sepsis 
(Stoll et al., 2002), have all been associated with the development of BPD in preterm infants. 
Moreover, hyperoxia, a potent inflammatory stimulus has been well described in the 
pathogenesis of BPD (Bhandari, 2010). Hence the above-mentioned inflammatory 
properties, in addition to its angiostatic attributes, make EMAP II very relevant cytokine in 
the pathogenesis of chronic lung diseases including emphysema and BPD.
POSSIBLE ROLE OF EMAP II IN CHRONIC LUNG DISEASE OF INFANCY
Over the years, the definition of BPD has evolved. In 1967, BPD was described by 
Northway et al, as severe cystic lung injury resulting from mechanical ventilation and 
oxygen exposure (Northway et al., 1967) whereas in this era BPD is characterized by 
alveolar simplification and restrictive lung physiology, as a result of arrest of alveolar 
development and inflammation (Northway et al., 1967; Coalson, 1997; Kinsella et al., 
2006). Despite numerous efforts, it still lacks effective treatment. Therefore, it is crucial to 
gain a better understanding on how alveoli and the underlying capillary network develop and 
how these mechanisms are disrupted in BPD. Studies indicate that the expression and 
signaling of the prominent angiogenic growth factor VEGF is impaired in BPD, contributing 
to the marked pulmonary vascular disease (Abman, 2010). Furthermore, infants that die with 
BPD have a marked reduction in VEGF and VEGFRs (Bhatt et al., 2001) making rescue of 
angiogenic signaling a critical component in BPD therapeutic approach (Thebaud et al., 
2005). Exogenous VEGF protects against O2-induced arrested alveolarization and 
stimulates lung vascular growth, but this results in immature and leaky vessels (Kasahara et 
al., 2000; Thebaud et al., 2005). Hence the exact pathophysiological role of VEGF in 
neonatal respiratory failure is not yet entirely clear. Current animal and human studies 
exhibit controversial results. Though animal models are invaluable tools in the study of 
human lung disease, multitude of differences in physiology make the findings less 
translatable to humans. Rightly, Bhandari has highlighted the importance of studying the 
temporal relationship of VEGF and lung development in human neonates and 
developmentally appropriate models with BPD (Meller and Bhandari, 2012). Also, a need 
arises to look at the contribution of other modulators of impaired vascular development and 
inflammation in this chronic lung dysplasia. EMAP II is one such suitable candidate, as its 
untimely overexpression could cause alveolar dysplasia secondary to its antiangiogenic and 
proinflammatory properties (Fig. 1). Furthermore, excess EMAP II inhibits VEGF ligand 
mediated signaling through the VEGFR1/2 receptors, interferes with endothelial cell 
adhesion resulting in apoptosis, and interferes with ECM deposition. These factors have all 
been found to directly contribute to lung dysplasia. Taken in conjunction with EMAP II’s 
ability to interrupt distal alveolar formation, induce lung dysplasia, interfere with alveolar 
type II → type I cell transdifferentiation, and impede cell–cell cohesion of pulmonary 
mesenchymal cells we believe that the excess EMAP II expressed in the lungs of premature 
infants directly contributes to the formation of distal alveolar dysplasia known as BPD.
Lal and Schwarz Page 8
Birth Defects Res A Clin Mol Teratol. Author manuscript; available in PMC 2015 March 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
EMAP II IN CHRONIC LUNG DISEASE OF ADULTS
Recent studies determined that EMAP II has a role in adult lung diseases where it has been 
recognized as a possible biomarker and modulator of cigarette smoke induced chronic 
obstructive pulmonary disease (COPD). Chronic lung disease of infancy and chronic lung 
disease of adulthood bear both pathological and clinical resemblances and a recent report 
suggests that infants with mild BPD have potential of developing COPD in adulthood owing 
to the similar impairments in respiratory mechanics and lung structure (Brostrom et al., 
2010). Moreover a potential link between COPD and BPD has been highlighted in various 
recent editorials (Filippone et al., 2010). Clauss et al. found that the EMAP II levels were 
elevated in the bronchoalveolar lavage of both current and ex-smokers and linked EMAP II 
to the pathogenesis of COPD. In murine models, they showed that EMAP II levels were 
increased in cigarette smoke induced emphysema. They conducted lung specific 
overexpression of EMAP II in transgenic mice that induced emphysema like changes 
(Clauss et al., 2011). In these experiments the mechanism of EMAP II up regulation 
involved an apoptosis-dependent feed forward loop, because caspase-3 instillation in the 
lung markedly increased EMAP II expression, while caspase inhibition decreased its 
production, even in transgenic EMAP II mice. Through this study, the authors suggested that 
EMAP II perpetuated the mechanism of lung emphysema in mice and is a suitable target for 
neutralization treatment. These findings raise further questions about the possible role of 
EMAP II in other chronic lung diseases such as BPD that has a very similar phenotype to 
emphysema.
In conclusion, it is clear that the vasculature plays an important role in normal lung 
development. Aberrations in normal pulmonary vascular development are involved in 
debilitating lung dysplasia’s like BPD. We speculate that EMAP II plays an important role 
in these processes and our current studies are further exploring the contribution that 
antiangiogenic proteins like EMAP II have in the pathogenesis of BPD.
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FIGURE 1. 
EMAP II’s antiangiogenic and pro-inflammatory properties may contribute to the pathologic 
processes associated with bronchopulmonary dysplasia.
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